Yudao Bio

About Yudao Bio

Yudao Bio, also known as Nutshell Therapeutics, is a biotechnology company established in December 2013, focusing on the discovery of allosteric drugs. The firm is led by a team that includes co-founder and CTO Dr. Zhentian Yu. Dr. Yu brings over two decades of drug development experience from roles at major pharmaceutical corporations like Novartis, where he was pivotal in establishing the computer-aided drug design platform in Shanghai and later directed innovation technology and academic cooperation. His extensive background in applying computational methods to drug discovery is central to Yudao Bio's operational strategy.

The company's core business revolves around tackling protein targets previously considered "undruggable." It addresses a significant challenge in the pharmaceutical industry, where approximately 85% of human proteins are difficult to target with conventional drugs. Yudao Bio develops small molecule drugs that modulate the function of these proteins by binding to allosteric sites—locations on a protein distinct from the active site. This approach can offer higher selectivity and a lower risk of toxicity compared to traditional methods.

Central to its operations is the proprietary ALLOSTAR™ platform, a system that integrates artificial intelligence, first-principles physics, and a comprehensive allosteric database to rationalize the discovery of these hidden binding sites and design molecules to interact with them. This platform aims to significantly reduce the time and cost associated with developing first-in-class and best-in-class drug candidates. Yudao Bio's business model is multifaceted, generating revenue through the internal development of its own drug pipelines, entering co-development partnerships with other biotech and pharmaceutical companies, and out-licensing its discoveries and platform technology. The company's clients are primarily other pharmaceutical and biotechnology firms that leverage its platform for their own drug discovery programs.